Back to Directory

Iris Mustich

Email

imustich@fhi360.org

Phone

919-627-6432

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
1216 Broadway
Suite 422
New York, NY 10001
United States of America

Request an Update

Affiliated Studies

IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children

DAIDS Number

Research Area

Study Status

IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

Research Area

Study Status

Closed to Accrual

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV

DAIDS Number

Research Area

Study Status

Closed to Follow Up